VTCN1 and cancer: In line with the identification of VTCN1 as a promising target for cancer treatment, its expression was associated with a shorter FP (HR:1.45, 95% CI 1.04–2.03, log rank p = 0.026) and a poor OS (HR:1.28, 95% CI 1–1.62, log rank p = 0.045) (Figure 3B).